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Abstract
Background:  Sexually transmitted infections (STIs) are hypothesized to play a role in the
development of prostate cancer, perhaps due to inflammation-induced oncogenesis. We assessed
in a nationally representative population of middle-aged men whether sexual behavior indicators
for an increased risk of genital infection were associated with serum prostate-specific antigen (PSA)
concentration, a marker of prostatic disease and inflammation.
Results: The percentage of men between the ages of 40 and 59 with a PSA ≥ 4.0 ng/ml was 2.6%
(95% confidence interval [CI], 1.8% – 3.8%). The percentage of men between the ages of 40 and 59
self-reporting a past diagnosis of genital warts or genital herpes, or a recent diagnosis of gonorrhea
or chlamydia is estimated to be 7.3% (95% CI, 6.2% – 8.6%). Men self-reporting that they had had
sex without using a condom in the past month had a lower PSA concentration and higher %fPSA
than those who did not. There were no associations between any of the other sexual activity or
laboratory measures and PSA or %fPSA.
Conclusion: In this nationally representative sample of middle-aged American men, we did not
find consistent evidence for an association between sexual behavior or a history of STIs and PSA
levels. Therefore, sexual factors are unlikely to lead to falsely elevated PSA tests in this population.
We cannot rule out the role of these factors in causing false positive PSA tests in subgroups of the
population that have a higher prevalence of high-risk sexual behavior, and more protracted or
recent exposures to these agents.
Background
Prostate cancer is a significant source of morbidity and
mortality around the world, yet its primary causes remain
a mystery. Two recent meta-analyses of mostly case-con-
trol studies have suggested that a history of sexually trans-
mitted infections (STIs), specifically human
papillomavirus (HPV) and Neisseria gonorrhoeae, may be
risk factors for prostate cancer. [1,2] Organisms infecting
the prostate may induce either symptomatic or asympto-
matic chronic prostatic inflammation, and several biolog-
ical hypotheses have been proposed to support
inflammation-induced prostate oncogenesis. [3] Cur-
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rently the links between infectious agents, inflammation,
and prostate cancer are poorly understood.
The prostate-specific antigen (PSA) test is commonly used
both as a screening tool and as a part of the diagnostic
workup to rule out prostate cancer. [4] Serum levels of
PSA are influenced by factors apart from the presence of
cancer and other prostatic conditions, including age, body
mass index,[5] and perhaps race[6] Serum PSA can be
divided into "free" and "complexed" portions depending
on whether the circulating PSA protein is bound to pro-
tease inhibitors. The ratio of free PSA to total PSA, called
the percent free PSA (%fPSA), is sometimes used as a
reflex test for an elevated PSA result, with a lower %fPSA
indicating an increased risk of prostate cancer[7]
PSA levels are known to increase during episodes of symp-
tomatic bacterial prostatitis,[8] and they have been shown
to vary by the histological extent of asymptomatic inflam-
mation[9,10] One cross-sectional study of men at an STI
clinic found an inverse association between age at first
intercourse and mean PSA, as well as a positive associa-
tion between higher titers of antibodies to Chlamydia tra-
chomatis  and PSA values. [11] High C. trachomatis
antibody titers are likely caused by multiple repeat infec-
tions, or chronic, asymptomatic infections. A longitudinal
study at two Baltimore STI clinics found that a subset of
men who present acutely with STIs experience a sharp
increase in PSA, suggesting that some non-ulcerating STIs
may progress to infect the prostate, ultimately inducing
inflammation. [12] These studies raise the question of a
potential association between high-risk sexual behavior or
STIs and increased PSA concentration. However, to date,
no studies have estimated the effect of this association in
a nationally representative population. In a population
screened for prostate cancer, changes in PSA due to these
factors may have additional importance, perhaps leading
to false-positive PSA screening tests. We evaluated the
association between sexual behavior, self-reported history
of STIs, and PSA concentration from the 2001–2004
National Health and Nutrition Examination Survey
(NHANES). Additionally, we examined the association of
serological evidence of infection with T. pallidum (syphi-
lis) or herpes simplex virus-2 (HSV-2) with serum PSA val-
ues. These STIs are themselves markers of high-risk sexual
behavior, [13] but have not been shown to directly infect
the prostate or to induce prostatic inflammation.
Results
Characteristics and demographics of this study popula-
tion have been described previously. [14] Of the 1513
interviewed men 40 to 59 years of age, 1456 (96.2%) par-
ticipated in the physical examination. Of these 1456 men,
29 (2.0%) did not provide consent for PSA testing, refused
to answer the consent question, or responded "don't
know," 36 (2.5%) were considered ineligible because of
other NHANES PSA exclusion criteria, an additional 65
(4.5%) men were missing information on either the con-
sent question or at least 1 of the exclusion criteria, and 33
(2.3%) were eligible but had a missing PSA result, leaving
a final study population of 1293 men (1293/1456, or
88.8% of all men between 40 and 59 years of age who par-
ticipated in the physical examination). For the subgroup
of men aged 40 to 49 similar percentages were excluded as
above (a total of 84 excluded out of 831), leaving 747 for
the analysis of this subgroup. Only 15 men were excluded
from this analysis because of recent infection or inflam-
mation of the prostate. The total number of respondents
varied for each question; for all sexual behavior questions
the percentage of missing and refusals varied from 0.5%
to 12.7%. Men who were excluded from our analysis had
the same median number of lifetime sexual partners, part-
ners in the last year, and partners in the last month as
those who were not excluded. Excluded men were not
more likely to report a past STI than non-excluded men (p
= 0.95). Race/ethnicity was not associated with PSA levels
in this sub-section of the NHANES population.
The percentage of men between the ages of 40 and 59 with
a PSA ≥ 4.0 ng/ml was 2.6% (95% confidence interval
[CI], 1.8% – 3.8%). The percentages of seropositivity for
T. pallidum and HSV-2 in men 40 to 49 years old are 1.6%
(95% CI, 1.1% – 2.4%) and 17.5% (95% CI, 13.9% –
21.7%), respectively. The percentage of men between the
ages of 40 and 59 self-reporting a past diagnosis of genital
warts or genital herpes, or a recent diagnosis of gonorrhea
or chlamydia is estimated at 7.3% (95% CI, 6.2% – 8.6%).
No trends were seen for predicted-margin geometric mean
PSA by age at first intercourse, the number of female sex
partners in the last year, or the number of female partners
in the past month (Table 1). An irregular pattern of pre-
dicted-margin geometric mean PSA levels was noted over
the number of lifetime sexual partners. Those men who
had had sex without a condom in the past month had a
lower predicted-margin geometric mean PSA than those
who had not (0.76 ng/ml vs. 1.15 ng/ml, p = 0.031). No
differences in predicted-margin geometric mean PSA were
seen by self-reported history of an STI, by circumcision
status, or by the antibody tests for HSV-2 and syphilis
infection (Table 1 and Table 2).
Men who reported having sex without a condom in the
past month had a higher %fPSA than those who did not
(Table 1). No associations were noted for %fPSA by any of
the other behavior variables. No significant differences in
%fPSA were seen by past HSV-2 or syphilis exposure as
determined from serum assays.Infectious Agents and Cancer 2007, 2:19 http://www.infectagentscancer.com/content/2/1/19
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Table 2: PSA Concentration by Serum Antibody Testing among PSA Eligible Men (Age 40–49), NHANES 2001 – 2004
Variable n Predicted margin 
geometric mean PSA (ng/ml)
p-value Predicted margin 
percent free PSA
p-value
Serum test for herpes simplex virus-2 exposure 737
Positive* 176 0.70 (0.63 to 0.77) 0.231 30.2 (28.1 to 32.4) 0.228
Negative or Indeterminate† 561 0.74 (0.70 yo 0.79) Reference 31.7 (30.4 to 33.0) Reference
Serum test for T. pallidum exposure 737
Current‡ or remote§ infection 27 0.84 (0.66 to 1.06) 0.253 28.7 (22.7 to 34.7) 0.398
No infection¶ 710 0.73 (0.69 to 0.78) Reference 31.5 (30.3 to 32.7) Reference
* Serum has antibodies to HSV-2 gP-2 protein † Three results were indeterminate
‡ positive or indeterminate
• positive or indeterminate EIA test for T. pallidum antibodies, and rapid plasma reagin (RPR) ≥ 8
§positive EIA test, and 1 ≤ RPR ≤ 8 and a positive T. pallidum-particle agglutination (TP-PA)
¶ negative EIA test, or positive or indeterminate EIA test and RPR score 0–8 and negative TP-PA
Table 1: Sexual Behavior and PSA Concentrations among US Men (Age 40 – 59), NHANES 2001 – 2004
Variable n Predicted margin geometric 
mean PSA (ng/ml)
p-value Predicted margin 
percent free PSA
p-value
Age at first intercourse (years) 1185
≤ 15 400 0.80 (0.73 to 0.89) Reference 30.3 (28.6 to 32.0) Reference
16 – 18 476 0.81(0.76 to 0.87) 0.833 31.1 (29.5 to 32.6) 0.561
≥ 19 309 0.82 (0.75 to 0.90) 0.802 31.3 (29.6 to 32.9) 0.417
Number of lifetime sexual 
partners
1169
0 – 3 268 0.83 (0.76 to 0.91) Reference 31.0 (29.2 to 32.7) Reference
4 – 5 181 0.94 (0.84 to 1.05) 0.072 31.3 (29.1 to 33.6) 0.820
6 – 10 268 0.73 (0.68 to 0.79) 0.069 31.4 (29.4 to 33.4) 0.783
11 – 20 193 0.91 (0.78 to 1.05) 0.345 29.2 (26.6 to 31.7) 0.317
20 + 259 0.73 (0.66 to 0.80) 0.072 31.4 (29.0 to 33.9) 0.767
Number of sexual partners in the 
past year
1190
0 155 0.78 (0.68 to 0.88) Reference 30.5 (28.1 to 32.9) Reference
1 854 0.82 (0.78 to 0.87) 0.471 31.1 (30.0 to 32.1) 0.703
≥ 2 181 0.79 (0.69 to 0.90) 0.916 30.3 (27.4 to 33.1) 0.882
Number of sexual partners in the 
past 30 days*
194
0 29 0.76 (0.58 to 1.00) Reference 30.8 (25.6 to 36.1) Reference
1 95 0.77 (0.65 to 0.92) 0.914 29.9 (27.1 to 32.6) 0.734
≥ 2 70 0.88 (0.70 to 1.11) 0.392 29.4 (24.1 to 34.7) 0.696
Have you had sex without a 
condom in the past 30 days?†
161
Yes 119 0.76 (0.66 to 0.88) Reference 30.8 (27.8 to 33.7) Reference
No 42 1.15 (0.81 to 1.63) 0.029 24.7 (19.0 to 30.3) 0.031
Are you circumcised? 1211
Yes 837 0.82 (0.77 to 0.86) Reference 31.1 (30.0 to 32.2) Reference
No 374 0.80 (0.72 to 0.90) 0.810 30.0 (27.3 to 32.7) 0.348
Self-reported history of STD 
infection
1182
Yes 77 0.85 (0.74 to 0.98) 0.517 28.5 (25.2 to 32.0) 0.151
No 1105 0.81 (0.77 to 0.85) Reference 31.1 (30.1 to 32.1) Reference
*Question asked only of men who have had >1 lifetime sexual partner
†Question asked only of men who have had at least one sexual partner in the past 30 days and had >1 lifetime sexual partnerInfectious Agents and Cancer 2007, 2:19 http://www.infectagentscancer.com/content/2/1/19
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Discussion
Our predominantly null results do not support a link
between sexual behavior or STIs and PSA concentrations
in this nationally representative sample of US men 40–59
years of age, with the exception of recent sex and condom
use. Therefore, sexual factors are unlikely to lead to falsely
elevated PSA tests in this population.
We found a statistically significant lower PSA concentra-
tion and a higher %fPSA in men who had had sex without
a condom in the last month. We are unsure as to why men
who have had recent unprotected sex would have a lower
PSA than those that have not. It should be noted that
these analyses were limited by small numbers of men, and
the possibility remains that this statistically significant
result is a chance finding.
There are several reasons for our predominantly null
results in this analysis. The lack of association between
PSA and the number of lifetime sexual partners or the
number of sexual partners in the last year may be because
past STIs never infected the prostate, or infected the pros-
tate but were treated and thus no longer induce inflamma-
tion. Additionally, men may have been infected
asymptomatically, and now report never having had an
STI. The antibody data collected in the NHANES do not
allow us to consider the precise time of infection or cur-
rent infection status of those testing positive for exposure
to HSV-2 or syphilis. These 2 organisms are not believed
to infect the prostate, and hence are unlikely to cause pro-
static inflammation themselves; we considered these
agents as surrogates for sexual behaviors and the opportu-
nity for the acquisition of other STIs that do infect the
prostate. Of the men self-reporting a past diagnosis of an
STI (n = 77), most reported either a genital warts or genital
herpes diagnosis (n = 71), and only 6 men reported a
diagnosis of gonorrhea or chlamydia. Given that the HPV
subtypes responsible for genital warts are rarely onco-
genic, and that HSV-2 is not known to infect the prostate,
we likely misclassified some of the men regarding likeli-
hood of prostatic inflammation. Furthermore, men were
asked to report gonorrhea and chlamydia diagnoses only
within the past 12 months. Therefore, men who had had
these infections in their young adulthood were combined
with men who had never been infected with N. gonorrhea
or C. trachomatis. All of these possible sources of misclas-
sification, which would have biased our results toward the
null, may have limited our ability to detect associations of
a small magnitude between sexual behavior and PSA con-
centrations.
The PSA component of the NHANES excluded any man
self-reporting current prostatic inflammation or infection,
a well-established elevator of serum PSA. [15] This crite-
rion likely excluded men with symptomatic prostatitis
from our study, but we likely included men with asymp-
tomatic chronic prostatitis because they are usually una-
ware of their condition. Men with mild prostatitis that has
not been diagnosed by a doctor are also possibly included
in this analysis. Because men with symptomatic prostatitis
were excluded we may have underestimated the associa-
tions of STIs and sexual behavior with PSA concentration.
We do not believe this is a substantial underestimation,
because in the antibiotic era it is likely that men undergo
curative treatment for a symptomatic STI before it infects
the prostate. Men who do not seek treatment for a symp-
tomatic STI likely make up a small portion of the general
US population.
It is likely that some proportion of the men in this analysis
had occult prostate cancer, which might have influenced
PSA concentration. However, the prevalence of cancer in
our study population is likely to be low, because all of our
participants were younger than 60. [16] The majority of
our analysis was restricted to men between the ages of 40
and 59. We do not feel this negatively impacts our analy-
sis, and it may be a positive aspect of it. The inflammatory
events that predispose men to later developprostate can-
cer are likely to have occurred many years prior to the
diagnosis. The chronic inflammatory state induced by
these events may be detectable as elevated PSA levels dur-
ing these pre-diagnosis years, the time period where our
cross-sectional analysis was conducted. One of the rea-
sons our analysisdid not find a positive association with
PSA could be that the infections precipitating the chronic
inflammatory state thatleads toprostate cancer occur-
mostly while men are older than the men in our study.
Prostate volume is also associated with serum PSA, [17]
and we were unable to control for it in our analysis. The
extent to which these 2 factors are associated with sexual
behavior or STIs is unknown, and it is possible that they
are confounders in this analysis.
The NHANES is not an ideal population in which to study
the association between PSA values and a specific STI for
a number of reasons. For one, the population is selected
and weighted to represent the US population as a whole,
not the high-risk sub-population you would expect to find
at an STI clinic. This limited the number of STIs captured
in this analysis, and forced us to collapse information into
binary variables, in the process losing information on the
association between PSA values and specific STIs. Another
methodological limitation is that the NHANES is a cross-
sectional study, and as such we have no information on
the participants' numbers of previous STIs, in the cases
where there was more than one episode of infection. This
would have been valuable information, as men with mul-
tiple previous infections are more likely to have had pros-
tate involvement. For these reasons we cannot rule out the
role of sexual factors in causing false positive PSA tests inInfectious Agents and Cancer 2007, 2:19 http://www.infectagentscancer.com/content/2/1/19
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subgroups of the population that have a higher prevalence
of high-risk sexual behavior, and more protracted or
recent exposures to these agents.
However, the NHANES population-based sampling is
also a strength of this analysis, allowing us to extrapolate
these results to the male US population. Nationally repre-
sentative analyses are ideal for studies of population-wide
screening tools such as the PSA test, because they reveal
the magnitude of potential associations over the entire
population that uses the test. This study suggests that the
prevalence of sexually transmitted infections of the pros-
tate in the overall US population is relatively low, leading
one to conclude that they do not greatly affect the accu-
racy of the PSA test at this population level.
Self-reported data on sexual behavior are susceptible to a
number of response biases. [18] The sexual behavior data
used in this analysis were collected using a computer-
based system that allowed respondents complete privacy.
Because of this enhanced privacy, computer-assisted self-
interviewing methods are believed to be least susceptible
to the motivational biases encountered commonly in
these assessments. However, over-reporting of low fre-
quency estimates and under-reporting of high frequency
estimates is a common source of misclassification and
may have influenced these results toward the null. [19]
Conclusion
We report no association between PSA levels and sexual
behavior or history of STIs in middle-aged American men.
In this population, sexual behavior or a history of STIs is
unlikely to affect PSA levels on a population-scale. We
cannot rule out the role of these factors in causing false
positive PSA tests in subgroups of the population that
have a higher prevalence of high-risk sexual behavior, and
more protracted or recent exposures to these agents.
Methods
The NHANES is a nationally representative weighted sam-
ple of the US population. It consists of three parts: a ques-
tionnaire, a medical examination, and a blood draw. A
description of the NHANES and the PSA testing compo-
nent has been published previously. [14] Serum PSA and
%fPSA was evaluated in all men aged 40 and older. Men
were excluded from the NHANES PSA examination if they
refused the PSA test, or if they self-reported a current infec-
tion or inflammatory condition of the prostate, having a
digital rectal examination within the last 7 days, having a
cystoscopy or biopsy within the last month, or having a
past diagnosis of prostate cancer.
We categorized self-reported race/ethnicity as non-His-
panic white, non-Hispanic black, Mexican American, and
other (other Hispanic men and all others). Participants
were asked about their age at first intercourse, and their
number of female sexual partners in the past year and over
their lifetime. Those with more than 1 sexual partner in
the last year were queried on the number of sexual part-
ners in the last 30 days. Those with at least 1 sexual part-
ner in the past 30 days were asked whether they had had
sex without a condom in the last 30 days. Men were also
asked if they had been told by a doctor or health profes-
sional in the last 12 months that they had chlamydia or
gonorrhea, or if they had ever been told by a doctor or
health professional they had genital herpes or genital
warts. Because of a low number of affirmative responses
(n = 77; 71 men reported genital warts or genital herpes,
6 reported a chlamydia or gonorrhea infection in the past
12 months), we combined these questions to form a
binary variable for any of these 4 self-reported STIs. Men
also self-reported whether they are circumcised. Sexual
history and behavior questions were not asked of partici-
pants who were older than 59.
The NHANES syphilis testing component consists of three
tests that determine history of exposure to T. pallidum: an
enzyme immunoassay for IgG antibodies to Treponema
antigens, a rapid plasma reagin assay for cell damage due
to possible Treponema infection, and a particle agglutina-
tion test for IgG antibodies to Treponema to confirm inde-
terminate results from the other 2 assays. [20] Those men
scoring 8 or higher on the rapid plasma reagin assay were
considered to have a recent infection with T. pallidum,
while those scoring less than 8 were classified as distantly
infected. Recent and distant infections were combined
because of the low number of Treponema-positive men
overall (27/737 = 3.7%). The HSV-2 NHANES testing con-
sists of an immunodot assay for the HSV-2-specific glyco-
protein gG-2. [21] Of the 737 men tested, 176, or 23.9%,
tested positive. Positive results are confirmed with a mon-
oclonal antibody inhibition assay. Antibody tests for
syphilis and HSV-2 were not conducted for participants
older than 49.
Predicted-margin geometric mean PSA concentration and
predicted-margin %fPSA, controlling for age and race/eth-
nicity, were calculated by sexual behaviors and STI status.
A predicted margin for a given group is the average pre-
dicted value for a population, assuming every member of
the population is in that group. [22] PSA values were log-
transformed to improve the normality of the distribution.
The %free values did not need to be log-transformed for
normality. Accordingly, geometric mean PSA values and
arithmetic mean %fPSA are reported in these analyses.
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